The Effects of Dietary Intervention on HIV Dyslipidaemia: A Systematic Review and Meta-Analysis

Clare Stradling1,2, Yen-Fu Chen2, Tracy Russell3, Martin Connock4, G. Neil Thomas5, Shahrad Taheri1,2,6

1 HIV Metabolic Clinic, Heart of England NHS Foundation Trust, Birmingham, United Kingdom, 2 Birmingham and Black Country NIHR CLAHRC, University of Birmingham, Birmingham, United Kingdom, 3 Dietetic Department, Western General Hospital, Edinburgh, United Kingdom, 4 Warwick Evidence, Warwick Medical School, University of Warwick, Coventry, United Kingdom, 5 School of Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, United Kingdom, 6 School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom

Abstract

Background: Efficacy of dietary intervention for treatment and prevention of HIV-related lipid disturbances has not been well established.

Methods: We conducted a systematic search of electronic databases supplemented with manual searches and conference abstracts, without language restriction. All randomised controlled trials (RCTs) with blood lipid outcomes, involving dietary intervention or supplementation for the treatment or prevention of adult HIV dyslipidaemia, versus no or other intervention were included. Two authors using predefined data fields, including study quality indicators, extracted data independently.

Results: Eighteen studies (n = 873) met our inclusion criteria. Seven RCTs for omega-3 supplementation (n = 372), and four RCTs for dietary intervention (n = 201) were meta-analysed using random-effects models. Mild statistical heterogeneity was observed. Dietary intervention reduced triglyceride levels by −0.46 mmol/l (95%CI: −0.85 to −0.07 mmol/l) compared to control. Omega-3 supplementation reduced triglyceride levels by −1.12 mmol/l (95%CI: −1.57 to −0.67 mmol/l) and total cholesterol, −0.36 mmol/l (95%CI: −0.67 to −0.05 mmol/l) compared to placebo/control.

Conclusions: Both omega-3 supplementation and dietary intervention reduced triglyceride level, with the latter possibly to a smaller extent. While dietary interventions are beneficial, more stringent dietary approaches may be necessary to fully address lipid disturbances in HIV patients.

Trial Registration: PROSPERO 2011:CRD42011001329.

Introduction

While survival with HIV has increased dramatically with highly active antiretroviral therapy (ART), affected individuals are experiencing metabolic complications including insulin resistance and dyslipidaemia, that ultimately translate to increased cardiovascular disease (CVD). Current guidelines recommend dietary intervention as first line treatment for HIV dyslipidaemia, [1,2,3] based on evidence from the general population, where it has been shown to reduce CVD risk and mortality. [4,5] Whether these findings can be extrapolated to the HIV population on ART is unknown. If dietary interventions were effective, CVD risk can be reduced through behaviour modification reducing toxicity and pill burden accompanying lipid-lowering medication (LLM).

Narrative reviews have examined the broader management of HIV dyslipidaemia including drug intervention, [6] and the effect of nutritional support and exercise on body composition. [7] Almeida et al examined dietary intervention from observation and intervention studies, concluding that there was little evidence for effectiveness of dietary interventions for HIV dyslipidaemia. [8]

We hypothesized that dietary interventions have a beneficial effect on HIV dyslipidaemia and carried out a systematic review and meta-analysis of randomised controlled trials (RCTs) assessing the efficacy of dietary interventions or supplementation for HIV dyslipidaemia.

Methods

Current guidelines for systematic reviews were followed [9] including protocol registration (PROSPERO 2011:CRD42011001329).
Search Strategy
A comprehensive search was conducted using a combination of MeSH and free text terms incorporating the population (HIV infected adults), intervention (any dietary therapy or supplements) and outcome (cardiovascular or dyslipidaemia), limited to human studies and clinical trials, up to 15 March 2012 on databases from Medline (OVID from 1950), AMED (from 1985), CINAHL, (from 1981), EMBASE (from 1988), and up to 31 May 2011 on OpenSIGLE (from 1980) and Cochrane Library, and clinical trial registries including the World Health Organisation and National Institutes of Health (Table S1). No language restrictions were used. The International AIDS Conference (2001 to 2010) and Conference on Retroviruses and Opportunistic Infections (1997 to 2010) websites were searched by use of the term ‘diet’.

Selection Criteria
Articles resulting from these searches and relevant references cited in those articles were screened and assessed independently by two reviewers (CS and TR) for eligibility. All RCTs involving dietary intervention or nutritional supplementation given for prevention or treatment of HIV metabolic disturbances in adults were included.

All-cause mortality or cardiac events were preferred as primary outcomes, however frequent reporting of these was not anticipated therefore surrogate markers such as change in serum lipids, were also sought. The control group was usual diet, no intervention or placebo; however, head to head intervention studies were also included. Studies lacking a control, or dietary intervention, or those whose primary focus was not prevention or treatment of metabolic disturbances were excluded. Duplicate publications were also excluded.

Validity Assessment
Study level risk of bias was assessed (independently in duplicate) using the Cochrane Collaboration 6-item domain based evaluation (version 5.0). [10] Diet specific factors, such as intervention adherence and potential confounding lifestyle factors (smoking, exercise, alcohol) were incorporated into the performance bias section (see Figure S1). A score of −1, 0, +1, was assigned to judgments ‘high’, ‘unclear’, and ‘low’ risk, respectively, for the purpose of study quality categorisation used to inform sensitivity analysis. Score consensus was reached following discussion of each study.

Data Extraction
Piloted forms and duplicate standardised databases were used by two reviewers to independently extract the following data: study characteristics (design, setting, enrolment date, sample size, eligibility criteria, quality, funding, ethics); population studied (baseline characteristics – lipids, body mass index, smoking, ART, ethnicity, age, gender, LLM), therapeutic interventions (duration, intensity, advice specifics regarding diet, exercise, smoking and adherence to it, comparison of intakes), and control regimen. Outcomes assessed included serum total cholesterol (total cholesterol), high-density lipoprotein cholesterol (HDL-cholesterol), Low-density lipoprotein cholesterol (LDL-cholesterol), and triglyceride (TG) levels. Discrepancies were resolved by discussion and comparison with the primary study report.

Data Analysis
No studies reported clinical endpoints, therefore outcome data (baseline and final mean values with standard deviation, SD) for total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride was extracted and converted to SI units. Authors were contacted for missing outcome data or raw data where non-parametric outcomes were presented and to clarify discrepancies. In absence of author response, the SD of the outcome mean for intervention and control groups was estimated from the respective standard error or confidence intervals if reported, or the p value of the mean difference between groups. In absence of reporting of final means, or where there was a significant difference between intervention and control group baseline values, change from baseline was used in the meta-analysis. Where clinical homogeneity allowed, effect sizes were pooled, and weighted by inverse variance of each study’s effect estimate. Studies reporting insufficient data were excluded from meta-analysis.

The principal summary measure was difference in mean lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride) post-intervention between groups. Due to broad eligibility criteria regarding dietary intervention, clinical heterogeneity was expected and a random effects model planned. Statistical heterogeneity was quantified using I² statistic and assessed for strength of evidence using the chi-squared test. Subgroup analysis was planned a priori where heterogeneity was anticipated between studies, arising from variations in baseline characteristics (normal or elevated lipid levels, use of LLM, use of ART), treatment type and duration, and comparators. Dose related response for omega-3 supplements was explored using meta-regression. Sensitivity analyses were pre-planned to assess the effect on the pooled result of exclusion of studies with small sample size (defined as less than 30 participants), studies of low quality, based on the risk of bias score (<2), unpublished studies, and inclusion of change scores within the analysis based on final values. Publication bias was explored using funnel plots where numbers of studies allowed (>10). Data were analyzed using RevMan 5.0 (The Cochrane Collaboration, UK) [11] and STATA 10 (StataCorp LP, Texas, USA).

Results
Literature searches retrieved 606 citations; after screening and exclusion, 43 articles were further scrutinised. (Excluded studies are listed in Figure S2). Eighteen primary studies met selection criteria (Figure 1). Three of these were from conference proceedings, available only in abstract form [12, 13] or with additional information from authors [14].

Study Characteristics
Table 1 shows key characteristics of included studies. Of 18 RCTs, seven were placebo-controlled, [12,15,16,17,18,19,20] and two used an alternative comparator, fenofibrate [21] or Mediterranean diet (MD). [22] All studies were in English, mainly from North America (n = 10), with some from Europe, [15,17,20] east Asia, [13,16,22] and South America. [14,23] Median study duration was 12 weeks (range: 8–16 weeks) for tablet (omega-3/other supplementation) studies and 26 weeks (range: 16–52 weeks) for diet studies. Sample sizes ranged from 11–120 participants (median: 46).

The majority of studies (12/18) involved specific nutrient supplementation: nine with omega-3 (daily dose range: 900–4860 mg total eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]; Table S2), three of which also included vitamin E. [20,21,24] Others employed a form of nicotinic acid [18,25] or chromium. [19].

Six studies evaluated dietary interventions. Due to lack of full text publication, very little was reported on dietary components of the symptom management model in one of the studies, [13] but
other studies were based on advice following the NCEP ATPIII dietary recommendations [26]. The specifics of these five diet studies varied, such as level of fibre, and inclusion of exercise, [14,23,27,28] whilst two studies also provided meals for 2–3 weeks [24,28] (Table S3). Intervention intensity varied from daily online support [28] or weekly individual counselling for six months, [27] to fortnightly [14] and three-monthly sessions. [23] Control groups in diet studies received usual care.

Most of the 873 participants in included studies were men (Table 2). Ethnicity ranged from 100% Chinese [22] and 100% Thai, [13] to most studies containing both African and Caucasian participants. Mean age ranged from 38–50 years. Mean baseline fasting triglyceride levels ranged 1.51–7.54 mmol/l and total cholesterol 3.94–6.24 mmol/l. Participants were generally on stable ART with hypertriglyceridaemia, except the Brazilian study where patients naïve to ART with and without dietary advice were observed for dyslipidaemia development. [23] The Chinese study mainly recruited newly diagnosed HIV patients. [22] Use of ART regimens containing protease inhibitors (PI) ranged from 14–82%.

Risk of Bias
Most studies were classified as low to moderate risk for selection, attrition, reporting and performance bias (Figure 2). Lack of blinding was the most common reason for high bias risk (Figure S3) and in diet studies this might have resulted in the control group also changing their diet due to trial participation, potentially producing bias against observing an effect of the intervention. Other main reasons for high bias risk were lack of information about attrition, lack of intention to treat analysis or power calculation, and potential imbalance at baseline in use of alcohol, cigarettes, or exercise. Randomisation information lacked clarity in half of studies.

Diet Studies
Among the six diet studies, two studies were excluded from meta-analysis due to lack of data, [13] and head-to-head design. [22] The pooled estimate for four studies (n = 201) [14,23,27,28] showed no significant differences between dietary intervention and control groups for total cholesterol (0.01 mmol/l; 95%CI −0.71 to 0.73, p = 0.97, I² = 85%); HDL-cholesterol (0.11 mmol/l; 95%CI −0.01 to 0.22, p = 0.07, I² = 33%); and LDL-cholesterol (3 studies; −0.01 mmol/l, 95%CI −0.81 to 0.79 mmol/l, p = 0.98, I² = 87%); and there was evidence of substantial statistical heterogeneity. Reduction in fasting triglycerides was significantly greater with dietary intervention versus controls, the random effects point estimate was: WMD −0.46 mmol/l, 95%CI −0.85 to −0.07 mmol/l (p = 0.02) (Figure 3) with moderate statistical heterogeneity (I² = 30%).

Similar treatment effect estimates were found on sensitivity analysis with exclusion of small trials (<30 participants), [27] duration of less than six months, intervention including exercise,
| STUDY                        | COUNTRY     | n/N       | INTERVENTION                                                                 | n/N     | CONTROL                  | DURATION   | OUTCOME MEASURE                          |
|-----------------------------|-------------|-----------|-------------------------------------------------------------------------------|---------|--------------------------|------------|------------------------------------------|
| Omega 3 supplementation     |             |           |                                                                               |         |                          |            |                                          |
| Peters 2012                 | Europe      | 23/25     | 2 g Omacor bd (4 × 460 mg EPA + 380 mg DHA + 4 mg vitamin E)                   | 25/25   | Matching placebo         | 12 weeks   | % change in TG                          |
| Thugsaard 2009              | Denmark     | 25/26     | 2 Omacor bd (4 × 460 mg EPA + 380 mg DHA + 4 mg vitamin E)                     | 23/25   | 2 corn oil bd            | 12 weeks   | TG                                       |
| Carter 2006                 | Australia   | 5/5       | 3 Maxepa tds (9 × EPA 180 mg + DHA 120 mg) + diet                             | 6/6     | Identical placebo + diet | 6 wks diet +8 wks tablets | TG + total cholesterol                     |
| DeTruchis 2007              | France      | 58/60     | Maxepa tds (EPA 1080 mg + DHA 720 mg) + diet                                  | 62/62   | Identical placebo + diet | 4 wk diet +8 wk tablets | % change in TG                          |
| Woods 2009                  | United States | 21/28     | 5 Omega Rx (5 × EPA 400 mg + DHA 200 mg) + 100 mg/d Vitamin E + diet            | 26/26   | usual diet; no advice    | 13 weeks   | TG at week 3 & 13                        |
| Wohl 2005                   | United States | Wk 4 24/26 | Fish oil (1750 mg EPA + 1150 mg DHA + 10 mg Vitamin E) + diet + exercise | Wk 4 20/26 | Diet + exercise          | 16 wks     | TG at wk 4                               |
| Baril 2007                  | Canada      | 26/30     | 1 g salmon oil tds (3 × 180 mg EPA + 120 mg DHA)                              | 31/36   | No placebo               | 24 weeks   | Change in TG                            |
| Peabody 2002ś                | Canada      | −14ś      | 300 mg omega 3 daily                                                          | −14ś    | Olive oil placebo        | 4 wk diet +8 wk tablets | TG, LDL, HDL, total cholesterol           |
| Gerber 2008                 | United States | 47/50     | 3 g fish oil bd (6 × 500 mg EPA + 310 mg DHA + 13 mg Vitamin E)               | 48/50   | 160 mg fenofibrate od    | 8 wks +8 wks | Response at wk 18 TG < 200 mg/dl on combination Rx |

**Dietary intervention**

| Fitch 2006                  | United States | 12/16     | NCEP style diet with weekly one-to-one counseling sessions + 3 hr exercise/wk = 10,000 steps/d | 16/18   | usual diet; one session with dietitian at baseline | 6 months   | change in waist circumference at week 24 |
| Sanchez 2006 ś              | Argentina    | 12/16     | NCEP style diet with sessions every 3 months + supervised resistance and aerobic exercise 3 times a week | 10/15   | usual diet + unsupervised resistance and aerobic exercise 3 times a week | 6 months   | within and between group change in total cholesterol, HDL-, glucose, insulin, limb fat assessed by DEXA at week 24 |
| Lazzaretti 2012             | Brazil       | 43/45     | Phase II NCEP diet with sessions every 3 months                                | 40/45   | usual diet; one session with dietitian at 12 months baseline | 6 months   | change in lipids at week 52             |
| Balasubramanyam 2011        | United States | 30/43     | NCEP style diet with sessions every 2 months + daily 30/41 internet support + supervised exercise 3 ×/week | 38/43   | Usual diet; booklet on healthy heart diet | 6 months   | Change in TG, HDL, non-HDL cholesterol |
| Ng 2011                     | Hong Kong    | 25/25     | Low fat diet (NCEP style) with sessions every 3 months23/23                   | 25/25   | Mediterranean diet (low sat fat +3 items from list) with sessions every 3 months | 12 months   | total cholesterol TG, WC, BMI, triceps skinfold thickness |
| Thanasilp 2010ś              | Thailand     | 19        | SMCSP Symptom management model + diet + yoga + Qi-gong                        | 23      | Routine nursing care     | 4 months   | LDL-, HDL-cholesterol                   |

**Other tablet supplementation**
Table 1. Cont.

| STUDY | COUNTRY | n/N | INTERVENTION | CONTROL | DURATION | OUTCOME MEASURE |
|-------|---------|-----|--------------|---------|----------|-----------------|
| Hadigan 2006 | United States | 11/11 | 250 mg acipimox tds | Identical placebo | 12 weeks | TG |
| Chow 2010 | United States | 10 | 1500 mg extended release niacin | No placebo | 16 wk.s | Flow mediated dilatation of branchial artery, HDL- |

Characteristics of the eighteen studies included in the qualitative synthesis: setting, sample size, intervention, control, and duration.

*median value.

1 unpublished data.

"estimated, not reported by study.

bd = twice daily.

tds = three times a day.

EPA = eicosapentaenoic acid.

DHA = docosahexaenoic acid.

NCEP = National Cholesterol Education Programme [26].

wk = week.

Ax = assessment.

DEXA = dual-energy x-ray absorptiometry.

doi:10.1371/journal.pone.0038121.t001

[14,27,28] change scores rather than final value, [14] unpublished trials [14,23] and those with high bias risk [23] (data not shown).

Omega-3

Of the nine omega-3 studies, two were excluded from meta-analyses due to lack of data [12] and head-to-head design [21] (Table S4). The excluded omega-3 trials illustrated extremes in both omega-3 doses and outcomes, from 13% reduction in triglyceride with 300 mg omega-3, [12] to 46% triglyceride reduction with 4860 mg omega-3 (versus 58% in fenofibrate comparison group). [21] Seven studies (n = 372) reported results for fasting triglycerides and total cholesterol and were included in meta-analysis. There was a significantly greater reduction in fasting triglycerides among those receiving omega-3, compared to controls; random effects point estimate −1.12 mmol/L, 95%CI −1.57 to −0.67 mmol/L (p<0.001, I² = 5%) (Figure 3). Total cholesterol reduction (−0.36 mmol/L, 95%CI −0.67 to −0.05 mmol/L, I² = 35%) (Figure 4) was significant (p = 0.02) when SD imputation used the average from other studies (SD = 1.23 and 1.24) as planned a priori, but was of borderline statistical significance (p = 0.05) when alternative SD imputation (at ‘reasonably high’ value SD = 1.5) was used in sensitivity analysis.

The pooled estimate from five studies (n = 240) indicated no significant difference between intervention and control groups for LDL-cholesterol (0.10 mmol/L, 95%CI −0.15 to 0.35 mmol/L, p = 0.43, I² = 0%), and the pooled estimate for 6 studies (n = 365) similarly indicated no difference for HDL-cholesterol (0.05 mmol/L, 95%CI 0.00 to 0.11 mmol/L, p = 0.07, I² = 0%, Figure S5).

Sensitivity analyses showed that methodological heterogeneity did not appear to influence effect estimates; the six studies with sample sizes ≥30 [15,17,20,24,29,30] and the four trials meeting quality criteria [15,17,20,29] produced results similar to the overall meta-analysis (triglycerides MD −1.10 mmol/L, 95%CI −1.60 to −0.61 and −1.10 mmol/L, 95%CI −1.82 to −0.39, respectively).

Subgroup analysis, according to whether placebo was used in the trial, did not demonstrate any differences in treatment effects (test for subgroup difference, triglyceride p = 0.62, total cholesterol p = 0.89). A significant difference in treatment effect between LLM subgroups, for cholesterol only, was found (test for subgroup difference p = 0.01), with trials allowing LLM use showing no significant treatment effect (−0.14 mmol/L, 95%CI −0.44 to 0.17) compared with those excluding LLM use (−0.81 mmol/L, 95%CI −1.25 to −0.37) (Figure 4). Thus, the moderate statistical heterogeneity among omega-3 studies for reduction in total cholesterol (I² = 35% as shown earlier) is likely due to the variability in exclusion criteria in relation to LLM use.

Risk stratification of studies suggested possible trends of increasing treatment effect with greater underlying risk, as defined by baseline triglyceride levels (Figure 3). Further exploration with meta-regression, however, found no evidence of a significant association between either baseline triglyceride levels (p = 0.1 and p = 0.6), omega-3 dose (p = 0.9 and p = 0.7) or proportion of participants on PI-based regimens (p = 0.4 and p = 0.6) and mean difference in triglycerides or total cholesterol, respectively, between intervention and control groups. Although the meta-regression was planned a priori, the small number of trials limited the statistical power of analyses, which remain exploratory.

Publication Bias

Small statistical heterogeneity was observed in the diet and omega-3 meta-analyses for triglycerides (I² = 30%, p = 0.23 and
### Table 2. Participant characteristics.

| STUDY | POPULATION | ELIGIBILITY CRITERIA | DRUGS | BASELINE LIPIDS (mmol/l) |
|-------|------------|----------------------|-------|-------------------------|
|       | Gender, mean age, ethnicity | Mean BMI, Smokers | ART | LLM | TG | total cholesterol |
| **Omega 3 supplementation** | | | | |
| Peters 2012 | 98% men 45 yrs, 90% white | BMI 24 | Fasting TG between 3.4–11.3 mmol/l on low cholesterol diet, avoiding excess alcohol | Stable ART >3 months 52% PIs 46% RTV | All on fibrate or niacin | 4.9 | 6.3 |
| Thugsaard 2009 | 78% men 45 yrs, 86% white smokers | BMI 24.7 31% smokers | All patients on ART | >3 months ART 47% PIs 8% | 1.67 | 5.45 |
| Carter 2006 | 100% men 48 yrs | BMI 24 | total cholesterol <6.5 mmol/l; TG 3.5–10 mmol/l | Stable ART >6 months 82% PIs | 18% | 5.06 | 5.77 |
| DeTruchis 2007 | 89% men 46 yrs | BMI 23 | TG ≥3.43 mmol/l + TG 2–10 g/l after 4 week TG lowering diet; glucose ≤6.6 mmol/l, alcohol ≤20 g/d | Stable ART ≥2 months 72% PIs | Nil | 4.5 | NR |
| Woods 2009 | 80% men 47 yrs* 50% white | BMI 19–30+ TG >1.69 mmol/l or insulin resistance | 87% on ART 63% PIs 50% RTV | 2 months 39% PIs | 5 | 2.01* | 5.08* |
| Wohl 2005 | 90% men 44 yrs 46% white | BMI 27 | TG >2.26 mmol/l | Stable ART >3 months 43% RTV | Yes %NR | 5.44 | 6.23 |
| Baril 2007 | 98% men, 49 yrs, 72% smokers (current or past) 14% DM | triglyceride 6–11 mmol/l, or triglyceride 2–6 mmol/l with total cholesterol:HDL-cholesterol ≥6 | Stable ART >6 months 60% 59% PIs | 5 | 6.05 |
| Peabody 2002 | 75% men 42 yrs | BMI 25 | triglyceride >3 mmol/l | On ART | NR | 4.42 | 5.71 |
| Gerber 2008 | 93% men 43 yrs* 57% white | triglyceride ≥4.5 mmol/l + LDL-cholesterol ≥4.1 mmol/l Adherence to lipid lowering diet and exercise for 28 d pre screening | ART >3 months 39% PIs | Nil | 7.54* | 6.33* |
| **Dietary intervention** | | | | |
| Fitch 2006 | 32% white, 45% smokers | Metabolic syndrome = 3/5 of: raised triglyceride, WC, or BP, fasting glucose, low HDL-cholesterol | stable ART >1 month 53% 9% | 2.48 | 5.14 |
| Sanchez 2005 | 74% men 42 yrs | BMI 25 52% smokers Lipodystrophy + no alcohol abuse + no Family History of dyslipidaemia | Stable ART >6 months Nil | 2.625 | 5.575 |
| Lazzaretti 2012 | 37% men 38 yrs | BMI 24 27% smokers No ART, no LLM, no history of CVD/dyslipidaemia (mean CD4 177) | naive to ART 19% started PIs | 3% started PIs | 1.52 | 3.943 |
| Balarasuramamy 2011 | 91% men 45 yrs 38% white smoking | BMI 27 62% Hx of smoking | Triglycerides between 1.7–11.3 mmol/l + BMI 19–35+ no LLM + CD4>100 | Stable ART >6 months 72% Nil | 3.62 | 5.63 |
| Ng 2011 | 77% men 41 yrs 0% white | BMI 22 | Not previously received diet advice + stable with HIV diagnosis and no current illness (many newly diagnosed and not stable) | 79% on ART 17% PIs | Yes %NR | 1.99 | 4.69 |
| Thanaysilp 2010 | 100% women | On ART | On ART | 100% on ART | | | |
| **Other tablet supplementation** | | | | |
| Hadigan 2006 | 74% men 46 yrs | BMI 27 | Lipodystrophy + triglyceride >1.69 mmol/l + no alcohol abuse | Stable ART >3 months 52% Nil PIs | 2.99 | 5.23 |
There was some evidence of asymmetry in the funnel plot (Figure S6). Potential causes include publication bias, genuine small study effects, and statistical heterogeneity; the latter was small and an unlikely explanation. [31] Formal testing of statistical significance of the asymmetry was not undertaken because of the small number of studies.

Other Supplementation

Three studies were excluded from the meta-analyses above due to their use of other forms of supplementation, rather than omega-3 or dietary intervention. Two small studies investigated the use of nicotinic acid analogues, reporting a significant reduction in triglycerides \(-0.54 \text{ mmol/l} \) versus placebo \(+0.65 \text{ mmol/l} \) (\(p = 0.01\)) in one, [18] and a significant increase in HDL-cholesterol \(+0.08 \text{ mmol/l} \) compared to control group \(-0.03 \text{ mmol/l} \) (\(p = 0.04\)) in the other. [25] Chromium supplementation was associated with improvement in insulin resistance and a significant reduction in triglycerides \(-0.54 \text{ mmol/l} \) (\(p = 0.03\)) in one study, where the effect was greater in participants with lipodystrophy \(-0.78 \pm 0.30 \text{ mmol/l} \) compared to those without \(0.14 \pm 0.19 \text{ mmol/l} \) (\(p = 0.017\)) [19] (Table S4).

Head-to-head Studies

A head-to-head study found no clinically significant difference in treatment effect between MD versus low fat diets (LFD). [22] The interventions appeared to differ in delivery rather than content. Trends for reducing total cholesterol levels with LFD, but maintaining triglyceride levels with MD were seen. Lack of study exclusion criteria resulted in a varied sample including unstable patients, those newly diagnosed with HIV or recently commenced on ART (Tables 2 and S4). [22].

Discussion

Findings

Dietary change is recommended to address deleterious lipid profiles predisposing to CVD in HIV patients. We did not find any studies reporting cardiovascular outcomes with dietary intervention in this patient population, therefore the objective outcome measures of serum lipids were used. Our meta-analysis revealed that a median dose of 2.8 g/d omega-3 was effective in reducing fasting triglycerides by \(-1.12 \text{ mmol/l} \) over an average treatment period of 12 weeks. Likewise NCEP Therapeutic Lifestyle Changes diets (TLC) [26] reduced fasting triglyceride reduction by \(-0.46 \text{ mmol/l} \) over an average treatment period of eight months in ART treated patients. Importantly, no significant effect on HDL-cholesterol or LDL-cholesterol was seen with either diet or omega-3 intervention, and only a minor reduction in total cholesterol was observed with omega-3 supplementation. These findings have good external validity coming from 5 different continents.

Interpretation of Findings

Dietary Intervention. In the general population, current evidence from meta-analyses suggest that dietary intervention reduces triglycerides by \(-0.12 \text{ mmol/l} \) (18.2%) with TLC style diets and exercise. [32] Previous reports of reductions of \(-0.17 \text{ mmol/l} \) (8%) and \(-0.19 \text{ mmol/l} \) (8%) with the Step I and Step II NCEP diets, respectively, may have been over estimated by outdated statistical approaches. [33] These are somewhat less than the reduction observed in our pooled estimate, presumably because of differences in baseline triglyceride levels (mean 2.20 mmol/l in the 3 HIV population diet studies versus 0.98 mmol/l in the general population studies [32]).
The lack of a beneficial effect of diet on HDL-cholesterol levels in our analysis, also observed by other reviews, [32,33] was potentially due to the diets’ emphasis on lowering saturated fat which also reduces HDL-cholesterol. [33,34] The positive effects of exercise on HDL-cholesterol [35,36] may also be insufficient to override the lowering effect of diet. [32].

We observed no differences for LDL-cholesterol. This was unexpected, as previous meta-analyses in the general population have shown significant reductions in LDL-cholesterol with diet. Reasons for this are uncertain but may include lack of diet intensity and adherence. Evidence from meta-analyses suggest an incremental effect on lipid lowering with diet intensity, from an LDL-cholesterol reduction of $-0.18 \text{mmol/L (95\%CI 0-1 to 0.27) with general dietary advice}$ [37] to $-0.49 \text{mmol/L (12\%)}$ with Step I, and $-0.65 \text{mmol/L (16\%)}$ with Step II NCEP diets. [33] Recent RCTs suggest that this treatment effect may be magnified with addition of a ‘portfolio’ of cholesterol-lowering foods: plant sterols, soy protein, viscous fibre, and almonds, to produce an LDL-cholesterol reduction $-1.36 \text{mmol/L (29-6\%)}$ in feeding trials. [38] However, when performed under real-life conditions, the LDL-cholesterol reduction was $-0.67 \text{mmol/L (13-8\%)}$ due dietary adherence of only 46%. [39] Higher intensity dietary interventions may also be required in the HIV population for LDL-cholesterol reduction. Changes in LDL-cholesterol may have been limited in the included studies by adherence, as measures revealed that although significant improvements to dietary intake were made with regard to fat and fibre, levels attained did not reach the goals set [23,24,27]/Figure S4). The significant reduction in total cholesterol observed in one of the included studies at week 3 (following controlled feeding), but not at week 13 [24] further supports the importance of dietary adherence, suggesting that dietary interventions may be difficult to implement in real-life, also seen in uncontrolled studies. [40].

Another difficulty with dietary interventions is establishing which components alter the outcome of interest and whether they act independently, synergistically or accumulatively. The magnitude of effect observed in the Woods study [24] could be explained by the dietary intervention enhancing triglyceride reduction as well as improving HDL-cholesterol levels synergistically with omega-3. It is unlikely that the addition of exercise [14,27] would affect the outcome of dietary intervention alone, as this intensity and duration of exercise has previously proved insufficient to reduce triglycerides. [41,42,43,44].

Omega-3. Our study supports a role for omega-3 supplementation in primary treatment of hypertriglyceridaemia in HIV patients. A systematic review in patients with diabetes (mean dose 3-5 g/d fish oil) reported similar reductions in triglycerides. [45] In primary prevention, from 47 RCTs [16,511 subjects], a mean dose 3-25 g/d and duration 24 weeks, reduced triglyceride by $-0.34 \text{mmol/L (95\%CI -0.41 to -0.27) from mean baseline 2.44 mmol/L}$. [46] The magnitude of triglyceride reduction was significantly related to baseline triglyceride and fish-oil dose, but not duration. We observed no evidence of a dose effect, probably due to the small number of studies; however in the general population, a $5-10\%$ reduction in triglycerides has been reported with every 1 g of EPA/DHA consumed. [47] Subgroup analysis in our review revealed significant total cholesterol reduction with omega-3 in patients who were not on statin therapy, highlighting the importance of explicit exclusion criteria in trials, as concurrent LLM likely masked the effect.

Omega-3 supplementation has a triglyceride-lowering effect that may impact on cardiac outcomes. Previously meta-analyses reported reductions in mortality and cardiovascular events [48,49,50] in patients with existing CVD who were taking fish oil supplements. However, they may have been subject to publication bias as inclusion of more recent trials (GISSI-HF,OMEGA, JELIS) produce pooled analyses of non-significant reduced mortality risk. [51] This suggests that doses of 1 g/d omega-3 cannot reduce mortality risk further than provided by optimised drug treatment. JELIS results suggest that the dose-dependent effect of EPA may be linked to reduction in...
triglycerides that is distinct from LDL-cholesterol reduction with LLM. Similarly, evidence from previous reviews that fish oil supplementation was associated with significant reduction in cardiac deaths [50] suggests that the higher dose 3–4 g/d needed to reduce triglycerides, inflammation, increase vascular reactivity, and reduce platelet function [52] may be more appropriate for primary and secondary prevention; therefore trials are required with higher doses.

Strengths and Limitations

Previous reviews have been narrative and examined the broader management of HIV dyslipidaemia. McGoldrick et al focused on drug intervention as their search criteria and did not identify any

| Study or Subgroup | Omega 3 tablets | Control | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|----------------|---------|----------------------------------|----------------------------------|
|                   | Mean | SD | Total | Mean | SD | Total | Weight |                              |
| 2.1.4.1 LLM       |      |    |       |      |    |       |        |                              |
| Thussgaard 2009   | 5.4  | 1.17 | 25 | 5.23 | 0.93 | 23 | 16.6% | 0.17 [-0.43, 0.77]           |
| Carter 2006       | 5.4  | 0.79 | 5  | 5.78 | 0.79 | 6  | 8.8%  | -0.38 [-1.32, 0.56]          |
| Baril 2007        | 5.9  | 1.2 | 26 | 5.9  | 1.1  | 31 | 16.4% | 0.00 [-0.60, 0.60]           |
| Wohl 2005         | 5.67 | 1.23 | 24 | 6.27 | 1.24 | 20 | 12.7% | -0.60 [-1.33, 0.13]          |
| Peters 2012       | 5.99 | 1.14 | 23 | 6.17 | 1.22 | 25 | 14.4% | -0.18 [-0.85, 0.49]          |
| Subtotal (95% CI) | 103  | | | 105 | 68.8% | -0.14 [-0.44, 0.17]        |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 3.03, df = 4 (P = 0.55); I^2 = 0% |
| Test for overall effect: Z = 0.88 (P = 0.38) |

| Study or Subgroup | Omega 3 tablets | Control | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|----------------|---------|----------------------------------|----------------------------------|
|                   | Mean | SD | Total | Mean | SD | Total | Weight |                              |
| 2.1.4.2 no LLM    |      |    |       |      |    |       |        |                              |
| Woods 2009        | 4.45 | 1.23 | 21  | 5.28 | 1.24 | 26 | 13.2% | -0.83 [-1.54, -0.12]         |
| De Truchis 2007   | 6.1  | 1.4 | 58  | 6.9  | 1.7  | 62 | 18.0% | -0.80 [-1.36, -0.24]         |
| Subtotal (95% CI) | 79   | | | 88  | 31.2% | -0.81 [-1.25, -0.37]        |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.00, df = 1 (P = 0.95); I^2 = 0% |
| Test for overall effect: Z = 3.63 (P = 0.0003) |
| Total (95% CI)    | 182  | | | 193 | 100.0% | -0.36 [-0.67, -0.05]       |
| Heterogeneity: Tau^2 = 0.06; Chi^2 = 9.20, df = 6 (P = 0.16); I^2 = 35% |
| Test for overall effect: Z = 2.26 (P = 0.02) |
| Test for subgroup differences: Chi^2 = 6.17, df = 1 (P = 0.01), I^2 = 83.8% |

Figure 4. Forest plot for effect of omega-3 supplementation on cholesterol levels (mmol/l). Studies are ranked from low to high baseline triglyceride levels. Illustrates subgroup analysis of concurrent use of lipid lowering medication (LLM) on treatment effects of omega-3 supplementation on Cholesterol levels.

doi:10.1371/journal.pone.0038121.g004
trials concerning diet or supplements. [6] Leyes et al described 4 intervention trials; 2 open label and 2 randomised, studying only the effect of statin therapy and exercise levels, but not diet. [7] The most recent narrative review concluded that there was little evidence on effectiveness of dietary interventions for prevention and control of HIV dyslipidaemia. [8] Our systematic review is the first to employ a comprehensive search strategy and meta-analysis and demonstrates a role for dietary intervention.

While results of this review are encouraging, they must be viewed with caution due to several limitations. The small number of dietary intervention studies included in the analyses, their small sample sizes and inclusion of participants with mild dyslipidaemia limited the capacity to detect changes in lipids due to Type 2 error. Whilst statements can be made regarding the effectiveness of omega-3 supplementation and hypotheses can be proposed regarding dietary intervention, the limited number of studies available for each specific intervention do not allow us to make definitive statements about the individual effectiveness of NCEP diets, niacin or chromium.

Also, regarding validity, most studies either had some methodological weakness or had certain elements of methodology inadequately reported (Figure 2, Figure S3). All diet studies lacked blinding, which is problematic in diet studies. Additionally, it is difficult to have an appropriate control intervention. 

Despite lack of evidence of statistical heterogeneity in the meta-analyses for triglycerides, clinical heterogeneity was anticipated between dietary intervention studies due to variations in interpretation of the extensive NCEP ATPIII diet guidelines (Table S3). Additionally, study objectives differed, where one [23] examined dietary intervention to prevent dyslipidaemia, whilst others sought to correct dyslipidaemia/lipodystrophy. [14,23,27] Omega-3 studies included for meta-analysis were clinically homogeneous vis-à-vis intervention, control, duration and outcome; the main variations included differing participant ethnicities, facilitating transferability of findings, and baseline triglyceride levels or omega-3 dose, which were examined through ranking (Figure 3). The underlying causes of dyslipidaemia and whether they were due to direct HIV drug effects could not be quantified due to the variety of ART used, however, treatment regimens remained unchanged for the duration of the studies.

Another issue was the general incomplete reporting of study design and outcome data, as this hampered synthesis of included studies, requiring estimation of standard deviations in four studies. Risk of bias was difficult to assess with respect to allocation concealment, and selective outcome reporting (Figure 2). Future studies need to also include data on potential confounding factors such as other lifestyle factors (e.g. use of alcohol, tobacco, physical activity), or treatment modalities (e.g. protease inhibitors).

Clinical Implications

Current HIV guidelines recommend diet and exercise as first line treatment. Given the limitations of available studies, our findings support a role for diet with respect to triglycerides, but not other lipids. Omega-3 supplementation was effective in lowering triglycerides and total cholesterol, but had no impact on LDL-cholesterol or HDL-cholesterol. Omega-3 supplementation is recommended as second line therapy to fibrates in American guidelines. [1] The 25% triglyceride reduction from omega-3 in our pooled analysis is nearly comparable to the 30% triglyceride reduction reported with fibrates in the general population. [54] Therefore, in ART-treated HIV patients, omega-3 may to be an alternative to fibrates, which may not be well tolerated and interact with PIs. Also, the total cholesterol reduction with omega-3 may obviate the need for statins, and their attendant side effects, in patients with primarily high triglycerides. Recent reviews have both questioned the role of omega-3 in cardiovascular event or mortality reduction [55] and reported a reduction in cardiac and overall mortality with omega-3 supplementation. [56] Specific studies are needed to examine these outcomes in ART treated HIV patients. Triglyceride levels represent an important biomarker of CVD, because of their association with atherogenic remnant particles [57] and their independent association with an increased risk of MI, seen in the prospective HIV DAD cohort. [58] However, the effect of diet on a single biomarker cannot be independently considered, and overall CVD risk should be considered.

Conclusions

Available studies have only reported on impact of dietary intervention on surrogate lipid markers in ART-treated HIV patients. Regarding lipid markers, our meta-analysis provides evidence for a comparable clinical benefit of dietary intervention or omega-3 supplementation in reducing triglycerides, but no effects on other lipids in patients without concurrent LLM.

Our findings support the view that lifestyle interventions are a reasonable first strategy in clinical practice to improve lipid profile. Current dietary approaches, however, may be insufficient to independently tackle HIV dyslipidaemia and associated CV risk. Studies with interventions of sufficient duration and intensity, including a wide range of cholesterol lowering dietary components, focusing on foods rather than nutrients are required to elucidate the full potential of dietary intervention on lipid biomarkers and CVD. These studies would benefit from both efficacy (as treated) and effectiveness (intention to treat) analyses to address proof of principle for individual dietary components and whether they reduce CVD in clinical practice.
Acknowledgments

We are grateful to trial authors for providing additional information.

References

1. Duke MP, Stein JH, Abern JA, Fichtenbaum CJ, Gerber JG, et al. (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations from the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37: 613–627.

2. Gazzard BG, Anderson J, Babiker A, Boffito M, Brooks G, et al. (2000) British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy. 2008. HIV Med 9: 563–608.

3. Lundgren JD, Battrag Y, Behrens G, De Wit S, Guaraldi G, et al. (2008) European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 9: 72–81.

4. Fos F, Cesar F, Abbate R, Gennini GI, Cassini A (2008) Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337: a1534.

5. Hjerkinn EM, Sandvik L, Hjermann I, Arnesen H (2004) Effect of diet intervention on longevity in healthy middle-aged men with combined hyperlipidemia. J Intern Med 255: 68–73.

6. McLordich C, Leet CL (2007) The management of dyslipidemias in antiretroviral-treated HIV infection: a systematic review. HIV Med 8: 325–334.

7. Leyes P, Martinez E, Forgas M (2006) Use of dietary, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review. Antivir Ther 13: 149–159.

8. Almeida LD, Giudici KV, Jaime PC (2009) [Dietary intake and dyslipidemia arising from combination antiretroviral therapy for HIV infection: a systematic review]. Arq Bras Endocrinol Metabol 53: 519–527.

9. Libarati A, Alman DG, Tetzlaff J, Mulfrow C, G, Hsuce PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.

10. Higgins J, Green S (2009) Cochrane Handbook for Systematic reviews of interventions. version 5.0 [updated September 2009] Available from www.cochrane-handbook.org. The Cochrane Collaboration.

11. Cochrane Collaboration (2008) Review Manager (RevMan) [Computer program version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration.

12. Peabody D, Remple V, Green T, Kalmar A, Frohlich J, et al. (2002) The Mediterranean diet and health status: meta-analysis. BMJ 337: a1334.

13. Thanasilp S (2009) Effects of symptom management combine with complementary and alternative medicines on quality of life in HIV-infected patients on HAART. XIV World AIDS Conference: Abstract ThPeB734.

14. Sanchez M, Belloso W, Rey R, Clara L, Barcan L, et al. (2006) Adherence to a Mediterranean diet and health status: meta-analysis. BMJ 337: a1534.

15. Thusgaard M, Christensen JH, Morn B, Andersen TS, Vige R, et al. (2009) The evidence for dietary prevention and treatment of cardiovascular disease. Am J Clin Nutr 89: 551–570.

16. Carter VM, Woolley I, Dolly N, Yuhasl I, Mijch A, et al. (2006) The Mediterranean diet and health status: meta-analysis. BMJ 337: a1534.

17. De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, et al. (2007) Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients on highly active antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metabol 96: 2236–2247.

18. Baril J, Kovacs CM, Trottier S, Roederer G, Martel AY, et al. (2007) Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clinical Trials 8: 400–413.

19. Wohl DA, Tien HC, Busby M, Cunningham G, MacNab B, et al. (2005) Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clinical Infectious Diseases 41: 1498–1504.

20. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, et al. (2011) Exercise training reduces central adiposity and improves metabolic indices in HIV-infected women: a meta-analysis of randomized controlled trials. BMC Med 9: 74.

21. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, et al. (2003) Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.

22. Frayling TM, Timpson NJ, Weedon MD, Elliott C, Perry JR, et al. (2007) A common variant in the FTO gene is associated with body mass index and risk of obesity. Science 316: 886–891.

23. Lazzaretti R, Kuhmmer R, Sprinz E, Polanczyk C, Ribeiro J (2012) Dietary interventions on dyslipidemia associated with highly active antiretroviral therapy in Human Immunodeficiency Virus type 1-infected individuals: a randomized trial. J Am Coll Cardiol 59: 979–988.

24. Woods MN, Wanke CA, Ling PR, Hendricks KM, Tang AM, et al. (2009) Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipids and insulin sensitivity in persons with HIV. American Journal of Clinical Nutrition 90: 1566–1578.

25. Chow DG, Stein JH, Seto TB, Mitchell C, Siriratanaavijak N, et al. (2010) Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS 24: 1019–1023.

26. National Cholesterol Education Program (NCEP) Expert Panel (2002) Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106: 3143–3142.

27. Fitch KV, Anderson EJ, Hubbard JL, Carpenter SJ, Waddell WR, et al. (2011) Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 20: 1043–1050.

28. Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, et al. (2011) Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and body weight in HIV-infected persons on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metabol 96: 2236–2247.

29. Van horn L, Mooney J, Pate R, Cameron B, Johnson D, et al. (2005) Exercise training reduces central adiposity and improves metabolic indices in HIV-infected women: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metabol 90: 632–638.

30. Anstey KM, Koopman C, Boulso N, Gove J, Mastro T, et al. (2004) The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 104: 256–271.

31. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, et al. (2003) Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.

32. Jenkins DJA, Jones PJH, Lamarche B, Kendall CWC, Faulkner D, et al. (2011) Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.

33. Jenkins DJA, Jones PJH, Lamarche B, Kendall CWC, Faulkner D, et al. (2011) Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.

34. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, et al. (2003) Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.

35. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, et al. (2003) Effects of dietary intervention on highly active antiretroviral therapy-related dyslipidemia. AIDS 16: 2079–2081.

36. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, et al. (2011) Triglycerides and Cardiovascular Disease. Circulation 123: 2292–2333.

37. Brunner E, Rees K, Ward K, Burke M, Thorogood M (2007) Dietary advice for reducing cardiovascular risk. Cochrane Database of Systematic Reviews: CD001226.

38. Baril J, Kovacs CM, Trottier S, Roederer G, Martel AY, et al. (2007) Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clinical Trials 8: 400–413.

39. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, et al. (2003) Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.

40. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, et al. (2003) Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.

41. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, et al. (2003) Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.
Dietary Intervention in HIV Dyslipidaemia

43. Dolan SE, Frontera W, Librizzi J, Ljungquist K, Juan S, et al. (2006) Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Arch Intern Med 166: 1225–1231.
44. Terry L, Spinuz E, Stein R, Medeiros NB, Oliveira J, et al. (2006) Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Medicine and Science in Sports and Exercise 38: 411–417.
45. Hartweg J, Perera R, Montori Victor M, Dinencen Sean F, Neil Andrew H, et al. (2008) Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews: CD003205.
46. Edick GD, Howe PR, Smith C, Priest R, Bensoussan A (2009) Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. International Journal of Cardiology: 4–16.
47. Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, et al. (March 2004) Effects of Omega-3 Fatty Acids on Cardiovascular Risk Factors and Intermediate Markers of Cardiovascular Disease. Rockville, MD: Agency for Healthcare Research and Quality: Tufts- New England Medical Center Evidence-based Practice Center.
48. Marik PE, Varon J (2009) Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clinical Cardiology: 363–372.
49. Zhao YT, Chen Q, Sun YX, Li XB, Zhang P, et al. (2009) Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Annals of Medicine: 301–310.
50. Leon H, Shibata MC, Sivakumar S, Dorgan M, Chatterley T, et al. (2009) Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 338: a2931.
51. Filion KB, El Khoury F, Biesinski M, Schiller I, Dendukuri N, et al. (2010) Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders: 24.
52. Eckel RH (2010) The Fish Oil Story Remains Fishy. Circulation 122: 2110–2112.
53. Heaney RP (2008) Nutrients, Endpoints, and the Problem of Proof. The Journal of Nutrition 138: 1591–1595.
54. Saha SA, Kizhakepunnur LG, Baliakar A, Arora RR (2007) The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 154: 943–953.
55. Hooper L, Thompson RL, Summerbell CD, Ness AR, et al. (2006) Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ: 752–760.
56. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC (2005) Effect of different antilipemic agents and diets on mortality: a systematic review. Arch Intern Med 165: 725–730.
57. Astrup A, Dyerberg J, Elwood PC, Heremans K, Hu FB, et al. (2011) The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr 93: 684–688.
58. Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, et al. (2011) Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS 25: 1497–1504. 1410.1097/QAD.1490b1013e32834917c32834916.